Conference Documentation: Asthma & COPD 4/15/2013 \| published by: SMI Publishing, Ltd ... previous Asthma & COPD, and COPD: Novel Therapeutics and Management Strategies events, Asthma & COPD 2013 will continue to bring forward leading industry experts and esteemed academic KOLs in the field to discuss the latest ... \| read more...	$788.78
Calming and Sleeping in Poland 4/11/2013 \| published by: Euromonitor International ... undertake any physical activity and often reach for unhealthy food products. All of these translate into an increasing number of anxiety and sleeping disorder incidents. Therefore demand for calming and sleeping products is on the ... \| read more...	$900.00
Bile Duct Cancer (Cholangiocarcinoma) – Pipeline Review, H1 2013 4/10/2013 \| published by: Global Markets Direct ... on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct ... \| read more...	$2,000.00
Disease and Therapy Review: Insomnia 4/10/2013 \| published by: Timely Data Resources, Inc. ... diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the sleep disorder market, as well as sales of leading drugs and therapies are provided. \| read more...	$950.00
Lung Cancer – Pipeline Review, H1 2013 4/10/2013 \| published by: Global Markets Direct ... for Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Cancer. Lung Cancer - Pipeline Review, Half Year ... \| read more...	$2,000.00
Chronic Pain – Pipeline Review, H1 2013 4/10/2013 \| published by: Global Markets Direct ... for Chronic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Pain. Chronic Pain - Pipeline Review, Half Year ... \| read more...	$2,000.00
Ovarian Cancer – Pipeline Review, H1 2013 4/10/2013 \| published by: Global Markets Direct ... for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. Ovarian Cancer - Pipeline Review, Half Year ... \| read more...	$2,500.00
Squamous Cell Carcinoma – Pipeline Review, H1 2013 4/10/2013 \| published by: Global Markets Direct ... therapeutic development for Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma. Squamous Cell Carcinoma ... \| read more...	$2,000.00
Calming and Sleeping in Azerbaijan 4/10/2013 \| published by: Euromonitor International ... also resulted in growing consumption of calming and sleeping products. Advertisements of these products through television and posters, as well as rising stress of urban living and working life, continued contributing to the growth. Euromonitor ... \| read more...	$900.00
Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H1 2013 4/10/2013 \| published by: Global Markets Direct ... provides information on the therapeutic development for Kidney Cancer (Renal Cell Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for ... \| read more...	$2,000.00
Pulmonary Arterial Hypertension – Pipeline Review, H1 2013 4/10/2013 \| published by: Global Markets Direct ... therapeutic development for Pulmonary Arterial Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension. Pulmonary Arterial Hypertension ... \| read more...	$2,000.00
Breast Cancer – Pipeline Review, H1 2013 4/10/2013 \| published by: Global Markets Direct ... for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer - Pipeline Review, Half Year ... \| read more...	$2,500.00
North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017 4/8/2013 \| published by: MarketsandMarkets ... delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on ... \| read more...	$4,650.00
Pipeline: Colorectal Cancer 4/4/2013 \| published by: Datamonitor ... III trials and the barriers to market entry remain high. Features and benefits Reviews candidates in development across the US, Japan, and five major EU markets so you can assess who and what your competitors ... \| read more...	$4,500.00
Calming and Sleeping in China 4/4/2013 \| published by: Euromonitor International ... body function decay, insomnia and dizziness, continued to be the driver of the calming and sleeping category. Moreover, white collar workers and students who face the pressure of fierce competition and heavy workloads have become ... \| read more...	$900.00
Calming and Sleeping in Chile 4/4/2013 \| published by: Euromonitor International ... as a growing number of Chileans suffer from stress and anxiety as a result of the hectic pace of modern life and economic uncertainty, sales increased in 2012. Euromonitor International's Calming and Sleeping in Chile ... \| read more...	$900.00
Immunoassays: Technologies and Global Markets - Focus on Diabetes Laboratory Immunoassays 4/1/2013 \| published by: BCC Research ... provided for 2011 and 2012, and projections, with five-year compound annual growth rates (CAGRs), through 2017. Discussion of government regulations and technology patents and the roles they play in development. Analysis of new markets. Comprehensive ... \| read more...	$4,400.00
Molecular Diagnostics in Cancer Testing 4/1/2013 \| published by: TriMark Publications ... first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays. These technologies are improving the discovery of therapeutic molecules for ... \| read more...	$3,400.00
Cough, Cold and Allergy (Hay Fever) Remedies in the US 4/1/2013 \| published by: Euromonitor International ... people out of confined indoor spaces where infection is more likely, limited cases of both flu and colds in the winter months. Conversely, those same climate factors increased both the intensity and the duration of ... \| read more...	$900.00
Competitor Analysis: Insulin 4/1/2013 \| published by: La Merie Publishing ... 2 diabetes mellitus. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by ... \| read more...	$590.00
PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 3/31/2013 \| published by: GlobalData ... Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy ... \| read more...	$4,995.00
PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022 3/31/2013 \| published by: GlobalData ... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ... \| read more...	$4,995.00
PharmaPoint: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022 3/31/2013 \| published by: GlobalData ... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ... \| read more...	$4,995.00
PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and Market Analysis to 2022 3/31/2013 \| published by: GlobalData ... (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying ... \| read more...	$4,995.00
EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022 3/31/2013 \| published by: GlobalData ... cancers in the world, representing almost 13% of all cancers (Ferlay et al., 2010). NSCLC is the most common type of lung cancer, comprising about 85% of all lung cancers. An estimated 1.37 million new ... \| read more...	$3,995.00

< prev 1 2 3 4 5 6 7 8 9 10 next >